Quick answers
- What is Combivent Respimat?
- Combivent Respimat is a brand name of Ipratropium bromide and albuterol sulfate, a prescription medicine. The FDA NDC Directory lists 1 Combivent Respimat product in 1 strength and form.
- Who makes Combivent Respimat?
- Boehringer Ingelheim holds the FDA application for Combivent Respimat (NDA021747, approved October 7, 2011).
- Is there a generic or store brand of Combivent Respimat?
- Other products of Ipratropium bromide and albuterol sulfate are listed with the FDA, but none in exactly the same strength and form as a Combivent Respimat product.
- What do pharmacies pay for Combivent Respimat?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Combivent Respimat strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Combivent Respimat been recalled?
- FDA enforcement reports list 1 recall of Combivent Respimat products; the newest started July 24, 2015. A recall usually concerns specific lots, not every product.
What Combivent Respimat is
Each Combivent Respimat product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Ipratropium bromide and albuterol sulfate · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| albuterol sulfate 100 ug · ipratropium bromide 20 ug spray, metered (respiratory (inhalation)) | Combivent Respimat | None listed | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Ipratropium bromide and albuterol sulfate →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA021747 | Boehringer Ingelheim | October 7, 2011 | 1 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| albuterol sulfate 100 ug · ipratropium bromide 20 ug spray, metered | Brand: Combivent Respimat | $124.15 per gram |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Combivent Respimat
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Combivent Respimat products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 24, 2015 · Class II · Terminated · D-1279-2015
Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.
COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray, 20 mcg/100 mcg per actuation*, 4 Grams, 120 Metered Doses per inhaler, Rx only, Distributed by Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefie — Boehringer Ingelheim Roxane Inc
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.